$6 billion acquisition! Medical giant Bausch Health plans to take a controlling stake in Surgery Partners (SGRY.US)
Boston Consulting Group plans to acquire a controlling stake in Surgery Partners for approximately $6 billions, at $20 per share; Bain Capital will retain a 40% stake, and the deal could be announced as early as Monday.
According to sources cited by Zhihui Caijing APP, Bon Secours Mercy Health is in late-stage negotiations to acquire a majority stake in surgery services provider Surgery Partners (SGRY.US). This transaction would value the Bain Capital-backed company at approximately $6 billion, including $3.5 billion in debt.
Bon Secours’ partial acquisition of Surgery Partners would value the company at about $20 per share. Bain Capital will retain its nearly 40% stake.
After over a year of efforts to find a buyer for Surgery Partners, this potential deal could be announced as early as Monday. Previously, Bain Capital abandoned a deal with an enterprise value of $6.7 billion.
Bon Secours operates 47 hospitals and generated about $14 billion in revenue last year. Surgery Partners operates 176 surgery centers and hospitals across 30 U.S. states.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MINIMAX drops 10.8% in 1 hour
The battle for customer loyalty heats up ahead of the holiday season! Walmart (WMT.US) launches a $120 membership package, going head-to-head with Amazon Prime and Costco.
Walmart launched a joint membership package for Walmart+ and Sam’s Club Plus this week, directly competing with Amazon Prime and Costco.
Data: ETH falls below 2,300 USD
Survival period doubled! AstraZeneca's new stomach cancer drug Sone-ve aims for $5 billion in annual sales, ADC takes another step towards replacing chemotherapy
AstraZeneca's gastric cancer ADC doubles patient survival, extending life by five more months, aiming for annual sales of $5 billion; the company is racing with Takeda and Astellas to target Claudin 18.2.
